Anti-tumor activity also plays a critical role during eye development in the embryo
Arf gene prevents exorbitant evolvement of blood vessels in the developing glad eye by blocking signals that trigger accumulation of cells that nurture these vessels, according to St. Jude researchers
A gene raise known for its role in preventing cancer also plays a key capacity in the developing embryo, where the gene prevents unreasonable growth of blood vessels, according to investigators at St. Jude Children’s Research Asylum.
The gene, called Arf, prevents the amassing of infallible cells, called pericytes, that nurture the growth of blood vessels in the eye during embryonic development, the researchers said. This observation is of concerned about because Arf also works with a gene called p53 to trigger apoptosis–programmed suicide–in cells that have become cancerous. In the eye, however, Arf works through a gal Friday mechanism, independent of p53. The au courant disclosure that Arf also restricts blood bark growth in the notion of the embryo was a surprising finding because it was not linked to its known role in suppressing cancer, the researchers said.
A circulate on this discovery appears in the online distribute of the European Molecular Biology Organization (EMBO) journal.
St. Jude investigators showed that the protein made by the Arf gene normally blocks signals that trigger the growth of pericytes. This blockage causes the network of blood vessels these cells nurture to degenerate. In the ahead of time embryo, this network, called the hyaloid vascular method, grows into the unclog, jelly-like area of the eye called the vitreous, between the lens of the lustfulness in front and the retina at the back of the eye. The network grows during the antique part of optic development, after which the blood vessels die and the network disappears. When this network persists–as it does in the paucity of Arf–it disrupts the ability of the developing leer to grow to its normal size–a disease called persistent hyperplastic primary vitreous. Children with this ready usually have abnormally close-fisted eyes and poor vision.
“The Arf gene is well known for its ability to sense when a room is being exceedingly stimulated to expand,” said Stephen X. Skapek, M.D., an assistant member of the Sphere of influence of Hematology-Oncology at St. Jude. “Arf then helps to trigger a series of signals to block cell proliferation. In the developing eye, we’ve demonstrated that Arf also blocks signals that would otherwise motive pericytes to duplicate and face the continued growth of blood vessels in the developing eye.”
This new percipience into the character of Arf was made credible by a laboratory model yesterday developed at St. Jude by a span led by Charles Sherr, M.D., Ph.D., and Martine Roussel, Ph.D., of the Genetics and Tumor Cell Biology Department (Zindy, F. et al., [2003] Proc Natl Acad Sci USA 100: 15930-15935).
“This model allowed us to observe the responsibility of Arf in its natural environment and to determine its function by studying the consequence on the developing eye of both the presence and insufficiency of this gene,” said Ricardo Silva, Ph.D., first architect of the EMBO tabloid and the postdoctoral schoolchild in Skapek’s laboratory who did much of the work on the current proposal. “The results of our scan capacity facilitate influence the increment of therapies for persistent hyperplastic primary vitreous.”
The development of the position of Arf in curtailing growth of blood vessels in the developing eye might also contribute to development of chic anticancer drugs. “If we can figure out how to re-set in motion the Arf gene in human cancers in which this gene is repressed, we effect be able to prevent the increase of perivascular cells that support the blood vessels that victual a tumor,” Skapek said. “A stupefy that lets us starve those solid cancers would be a powerful new weapon against cancer.”
The researchers showed that the Arf gene in the pericytes disrupts the hyaloid vascular system in the embryonic glad eye by blocking the cell’s ability to counter to a signaling molecule called platelet-derived enlargement factor ([Pdgf]-B). Pdgf-B triggers this signal by binding to a receptor called Pdgf-beta on the surface of the pericyte.
Other authors of the archives catalogue J. Derek Thornton, Amy C. Martin, Jerold E. Rehg, David Bertwistle and Frederique Zindy. This free was supported in part by the American Cancer Society, the State Examine Institute and ALSAC.
St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital is internationally recognized in support of its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by belatedly entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities on all sides of the just ecstatic. No derivation ever pays for treatments not covered by insurance, and families without insurance are never asked to fork out. St. Jude is financially supported by ALSAC, its pay for-raising categorizing. For more information, please visit http://www.stjude.org.
